HS Diagnomics GmbH

HSDiagnomics was founded in late 2012. Inspired by several years of research about T-cell receptors and the enormous possibilities of modern Next-Generation-Sequencing plus tailored bioinformatics tools we came to the conclusion that our protocols and methods for target-specific amplification of TCRbeta loci from genomic DNA samples provide a key to profiling and understanding the adaptive immune system. With our proprietary TCRsafe® technology, we believe that even large-scale screens on TCRbeta profiles under various conditions can be carried out in a robust and quantitative way, without risk of carryover contamination. HSDiagnomics (HSD) offers a fully integrated service to customers, which opens new possibilities for all scientific and R&D projects investigating the role of T-cells under diverse conditions (treatments, vaccination, diseases, etc.). With our experts and technology at hand our customers will save time, budget and staff resources, since there is no need to set up and evaluate primer systems or develop dedicated software solutions. Within days we can deliver results, which bring you directly to the important questions. Over the last years we developed a method to identify tumor-specific T-cells with knowing the respective antigen in lung cancer. In addition we established a protocol to find tumor-specific T-cells which are shared between broad groups of different patients and even distinct cancer types.